Ascendis Pharma A  (ASND)
Other Ticker:  
Price: $127.6400 $-0.20 -0.156%
Day's High: $128.649 Week Perf: -2.92 %
Day's Low: $ 124.58 30 Day Perf: 2.9 %
Volume (M): 209 52 Wk High: $ 161.00
Volume (M$): $ 26,677 52 Wk Avg: $116.08
Open: $126.36 52 Wk Low: $85.08

 Market Capitalization (Millions $) 7,157
 Shares Outstanding (Millions) 56
 Employees -
 Revenues (TTM) (Millions $) 57
 Net Income (TTM) (Millions $) -653
 Cash Flow (TTM) (Millions $) 500
 Capital Exp. (TTM) (Millions $) 16

Ascendis Pharma A
Ascendis Pharma A is a biopharmaceutical company that specializes in developing innovative therapies for rare endocrine diseases. The company is focused on utilizing its proprietary TransCon technology platform to create long-acting prodrug therapies. These therapies aim to improve patients' lives by providing sustained release and targeted treatment options, reducing the burden of frequent dosing and improving efficacy. Ascendis Pharma is known for its strong pipeline of product candidates, including treatments for conditions such as growth hormone deficiency, adult growth hormone deficiency, hypoparathyroidism, and others. The company is committed to advancing scientific research and delivering transformative therapies to patients in need.

   Company Address: Tuborg Boulevard 12 Hellerup 0
   Company Phone Number: 70 22 22 44   Stock Exchange / Ticker: NASDAQ ASND


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Ascendis Pharma Unveils Promising Data on Novel Therapies at ASCO 2024

Published Mon, Jun 3 2024 8:01 PM UTC

Ascendis Pharma Presents New Data on Promising Treatments at ASCO 2024Ascendis Pharma, a biopharmaceutical company based in Denmark, has recently presented new data and updated results from its clinical trials at the American Society of Clinical Oncology (ASCO) 2024 conference. The findings highlight the efficacy and safety of their innovative treatment approaches.In the ini...

Product Service News

Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism

Published Tue, May 14 2024 6:32 PM UTC

Ascendis Pharma Extends FDA Review, Expands Market Reach with YORVIPATH, and Unveils Vision 2030In a series of significant developments, Ascendis Pharma A/S (Nasdaq: ASND) has strategically extended its market presence and set ambitious long-term goals while navigating regulatory complexions. The Danish biopharmaceutical leader announced today that the U.S. Food and Drug Ad...

Product Service News

Transforming Renal Health: TransCon PTH Shows Significant and Sustained Improvements in Chronic Hypoparathyroidism

Published Mon, May 13 2024 12:30 PM UTC

Improving Renal Function in Adults with Chronic Hypoparathyroidism: TransCon PTH Shows Promising Results According to Ascendis Pharma's Phase 3 PaTHway TrialCOPENHAGEN, Denmark, May 13, 2024 - Ascendis Pharma A/S (Nasdaq: ASND) recently revealed their two-year findings from a post-hoc analysis conducted on their Phase 3 PaTHway trial. This analysis demonstrates significant a...

Clinical Study

Pioneering the Future of Endocrinological Therapies: Ascendis Pharma's TransCon PTH and TransCon hGH Show Promise in Addressing Chronic Hypoparathyroidism and Growth Hormone Deficiency

Published Thu, May 9 2024 12:30 PM UTC

The renowned pharmaceutical organization, Ascendis Pharma A/S, has recently achieved significant strides in the therapeutic advancement for patients suffering from chronic hypoparathyroidism and growth hormone deficiency. The company's novel technologies, TransCon PTH (palopegteriparatide) and TransCon hGH (lonapegsomatropin), have gained due recognition for their exceptiona...

Product Service News

Ascendis Pharma Unveils YORVIPATH for Chronic Hypoparathyroidism, Evolving Treatment for Patients in Germany and Austria

Published Wed, Jan 31 2024 9:01 PM UTC

Ascendis Pharma Launches 2nd TransCon Product: YORVIPATH Now Available in Germany and Austria for Adults with Chronic HypoparathyroidismCOPENHAGEN, Denmark - Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company specializing in the development of innovative therapies, has recently announced the commercial launch of its second TransCon product, YORVIPATH (palopegter...


Ascendis Pharma A's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com